Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Terns Pharmaceuticals (TERN) Assets Average (2021 - 2025)

Terns Pharmaceuticals filings provide 5 years of Assets Average readings, the most recent being $663.4 million for Q4 2025.

  • Quarterly Assets Average rose 78.77% to $663.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $663.4 million through Dec 2025, up 78.77% year-over-year, with the annual reading at $694.5 million for FY2025, 119.62% up from the prior year.
  • Assets Average hit $663.4 million in Q4 2025 for Terns Pharmaceuticals, up from $311.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $663.4 million in Q4 2025 and bottomed at $145.8 million in Q1 2021.
  • Average Assets Average over 5 years is $269.4 million, with a median of $263.9 million recorded in 2023.
  • The largest annual shift saw Assets Average decreased 22.14% in 2022 before it soared 96.0% in 2023.
  • Terns Pharmaceuticals' Assets Average stood at $174.0 million in 2021, then skyrocketed by 37.84% to $239.8 million in 2022, then grew by 12.63% to $270.1 million in 2023, then surged by 37.39% to $371.1 million in 2024, then skyrocketed by 78.77% to $663.4 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Assets Average are $663.4 million (Q4 2025), $311.0 million (Q3 2025), and $329.9 million (Q2 2025).